Zdrowie i gospodarka · 28/09/2017

FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2018

The US Food and Drug Administration (FDA) has set the fee for using a rare pediatric disease priority review voucher for fiscal year 2018, based on the average costs incurred in reviewing human drug applications in the previous year.